http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 28 Aug 2026 16:25:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-QA+++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+30/26998376.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260828/AV2ZL22FZZ2ROJZA22ZF2ZYJI6GRZZ22ZS86">http://archive.fast-edgar.com/20260828/AV2ZL22FZZ2ROJZA22ZF2ZYJI6GRZZ22ZS86</a></p> <p> Filed on: August 28, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++10-QA+++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+30/26998376.html Fri, 28 Aug 2026 16:25:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++10-QA+++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+30/26998376.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260828/AV2ZL22FZZ2ROJZA22ZF2ZYJI6GRZZ22ZS86">http://archive.fast-edgar.com/20260828/AV2ZL22FZZ2ROJZA22ZF2ZYJI6GRZZ22ZS86</a></p> <p> Filed on: August 28, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++10-QA+++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+30/26998376.html Fri, 28 Aug 2026 16:25:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++10-QA+++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Mar+31/26998305.html si-local-file:///var/storage/secattach/20260828/26998305.html http://www.streetinsider.com/SEC+Filings/Form++10-QA+++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Mar+31/26998305.html Fri, 28 Aug 2026 16:21:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++10-QA+++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Mar+31/26998305.html si-local-file:///var/storage/secattach/20260828/26998305.html http://www.streetinsider.com/SEC+Filings/Form++10-QA+++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Mar+31/26998305.html Fri, 28 Aug 2026 16:21:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Aug+13/26931376.html si-local-file:///var/storage/secattach/20260814/26931376.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Aug+13/26931376.html Fri, 14 Aug 2026 16:31:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Aug+13/26931376.html si-local-file:///var/storage/secattach/20260814/26931376.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Aug+13/26931376.html Fri, 14 Aug 2026 16:31:00 -0400 O.02783319 OPK http://www.streetinsider.com/Corporate+News/OPKO+Health+raises+%24125M+in+notes+backed+by+mazdutide+royalties/26917629.html <p>OPKO Health, Inc. (NASDAQ: OPK) has issued $125 million in senior secured notes to HealthCare Royalty, a business of KKR (NYSE: KKR), secured by OPKO's royalty interests from its mazdutide license agreement with Eli Lilly and Company. The notes mature in 2044.</p><p>The financing caps total payments at 1.5 times the amount funded, after which OPKO retains future royalty economics associated with the financed stream. The company describes the arrangement as non-dilutive capital.</p><p>Mazdutide is being commercialized in China by Innovent Biologics under a licensing arrangement with Eli Lilly. OPKO recorded its first mazdutide royalty revenue in 2025 following commercial launch in http://www.streetinsider.com/Corporate+News/OPKO+Health+raises+%24125M+in+notes+backed+by+mazdutide+royalties/26917629.html Thu, 13 Aug 2026 09:15:48 -0400 KKR OPK http://www.streetinsider.com/Corporate+News/OPKO+Health+raises+%24125M+in+notes+backed+by+mazdutide+royalties/26917629.html <p>OPKO Health, Inc. (NASDAQ: OPK) has issued $125 million in senior secured notes to HealthCare Royalty, a business of KKR (NYSE: KKR), secured by OPKO's royalty interests from its mazdutide license agreement with Eli Lilly and Company. The notes mature in 2044.</p><p>The financing caps total payments at 1.5 times the amount funded, after which OPKO retains future royalty economics associated with the financed stream. The company describes the arrangement as non-dilutive capital.</p><p>Mazdutide is being commercialized in China by Innovent Biologics under a licensing arrangement with Eli Lilly. OPKO recorded its first mazdutide royalty revenue in 2025 following commercial launch in http://www.streetinsider.com/Corporate+News/OPKO+Health+raises+%24125M+in+notes+backed+by+mazdutide+royalties/26917629.html Thu, 13 Aug 2026 09:15:48 -0400 KKR OPK http://www.streetinsider.com/Hot+Corp.+News/OPKO+Health+raises+%24125M+in+notes+backed+by+mazdutide+royalties/26917629.html <p>OPKO Health, Inc. (NASDAQ: OPK) has issued $125 million in senior secured notes to HealthCare Royalty, a business of KKR (NYSE: KKR), secured by OPKO's royalty interests from its mazdutide license agreement with Eli Lilly and Company. The notes mature in 2044.</p><p>The financing caps total payments at 1.5 times the amount funded, after which OPKO retains future royalty economics associated with the financed stream. The company describes the arrangement as non-dilutive capital.</p><p>Mazdutide is being commercialized in China by Innovent Biologics under a licensing arrangement with Eli Lilly. OPKO recorded its first mazdutide royalty revenue in 2025 following commercial launch in http://www.streetinsider.com/Hot+Corp.+News/OPKO+Health+raises+%24125M+in+notes+backed+by+mazdutide+royalties/26917629.html Thu, 13 Aug 2026 09:15:48 -0400 KKR OPK http://www.streetinsider.com/Hot+Corp.+News/OPKO+Health+raises+%24125M+in+notes+backed+by+mazdutide+royalties/26917629.html <p>OPKO Health, Inc. (NASDAQ: OPK) has issued $125 million in senior secured notes to HealthCare Royalty, a business of KKR (NYSE: KKR), secured by OPKO's royalty interests from its mazdutide license agreement with Eli Lilly and Company. The notes mature in 2044.</p><p>The financing caps total payments at 1.5 times the amount funded, after which OPKO retains future royalty economics associated with the financed stream. The company describes the arrangement as non-dilutive capital.</p><p>Mazdutide is being commercialized in China by Innovent Biologics under a licensing arrangement with Eli Lilly. OPKO recorded its first mazdutide royalty revenue in 2025 following commercial launch in http://www.streetinsider.com/Hot+Corp.+News/OPKO+Health+raises+%24125M+in+notes+backed+by+mazdutide+royalties/26917629.html Thu, 13 Aug 2026 09:15:48 -0400 KKR OPK http://www.streetinsider.com/Press+Releases/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html <p align="justify">MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- <strong>OPKO Health, Inc. (NASDAQ: OPK) </strong>today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement.</p> <p align="justify">The transaction provides OPKO with additional non-dilutive capital while preserving significant long-term http://www.streetinsider.com/Press+Releases/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html Thu, 13 Aug 2026 09:15:00 -0400 A.50202447 KKR O.02783319 O.14891823 O.51351764 OPK http://www.streetinsider.com/Press+Releases/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html <p align="justify">MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- <strong>OPKO Health, Inc. (NASDAQ: OPK) </strong>today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement.</p> <p align="justify">The transaction provides OPKO with additional non-dilutive capital while preserving significant long-term http://www.streetinsider.com/Press+Releases/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html Thu, 13 Aug 2026 09:15:00 -0400 A.50202447 KKR O.02783319 O.14891823 O.51351764 OPK http://www.streetinsider.com/Press+Releases/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html <p align="justify">MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- <strong>OPKO Health, Inc. (NASDAQ: OPK) </strong>today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement.</p> <p align="justify">The transaction provides OPKO with additional non-dilutive capital while preserving significant long-term http://www.streetinsider.com/Press+Releases/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html Thu, 13 Aug 2026 09:15:00 -0400 A.50202447 KKR O.02783319 O.14891823 O.51351764 OPK http://www.streetinsider.com/Press+Releases/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html <p align="justify">MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- <strong>OPKO Health, Inc. (NASDAQ: OPK) </strong>today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement.</p> <p align="justify">The transaction provides OPKO with additional non-dilutive capital while preserving significant long-term http://www.streetinsider.com/Press+Releases/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html Thu, 13 Aug 2026 09:15:00 -0400 A.50202447 KKR O.02783319 O.14891823 O.51351764 OPK http://www.streetinsider.com/Press+Releases/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html <p align="justify">MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- <strong>OPKO Health, Inc. (NASDAQ: OPK) </strong>today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement.</p> <p align="justify">The transaction provides OPKO with additional non-dilutive capital while preserving significant long-term http://www.streetinsider.com/Press+Releases/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html Thu, 13 Aug 2026 09:15:00 -0400 A.50202447 KKR O.02783319 O.14891823 O.51351764 OPK http://www.streetinsider.com/Press+Releases/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html <p align="justify">MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- <strong>OPKO Health, Inc. (NASDAQ: OPK) </strong>today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement.</p> <p align="justify">The transaction provides OPKO with additional non-dilutive capital while preserving significant long-term http://www.streetinsider.com/Press+Releases/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html Thu, 13 Aug 2026 09:15:00 -0400 A.50202447 KKR O.02783319 O.14891823 O.51351764 OPK http://www.streetinsider.com/Globe+Newswire/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html <p align="justify">MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- <strong>OPKO Health, Inc. (NASDAQ: OPK) </strong>today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement.</p> <p align="justify">The transaction provides OPKO with additional non-dilutive capital while preserving significant long-term http://www.streetinsider.com/Globe+Newswire/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html Thu, 13 Aug 2026 09:15:00 -0400 A.50202447 KKR O.02783319 O.14891823 O.51351764 OPK http://www.streetinsider.com/Globe+Newswire/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html <p align="justify">MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- <strong>OPKO Health, Inc. (NASDAQ: OPK) </strong>today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement.</p> <p align="justify">The transaction provides OPKO with additional non-dilutive capital while preserving significant long-term http://www.streetinsider.com/Globe+Newswire/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html Thu, 13 Aug 2026 09:15:00 -0400 A.50202447 KKR O.02783319 O.14891823 O.51351764 OPK http://www.streetinsider.com/Globe+Newswire/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html <p align="justify">MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- <strong>OPKO Health, Inc. (NASDAQ: OPK) </strong>today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement.</p> <p align="justify">The transaction provides OPKO with additional non-dilutive capital while preserving significant long-term http://www.streetinsider.com/Globe+Newswire/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html Thu, 13 Aug 2026 09:15:00 -0400 A.50202447 KKR O.02783319 O.14891823 O.51351764 OPK http://www.streetinsider.com/Globe+Newswire/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html <p align="justify">MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- <strong>OPKO Health, Inc. (NASDAQ: OPK) </strong>today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement.</p> <p align="justify">The transaction provides OPKO with additional non-dilutive capital while preserving significant long-term http://www.streetinsider.com/Globe+Newswire/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html Thu, 13 Aug 2026 09:15:00 -0400 A.50202447 KKR O.02783319 O.14891823 O.51351764 OPK http://www.streetinsider.com/Globe+Newswire/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html <p align="justify">MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- <strong>OPKO Health, Inc. (NASDAQ: OPK) </strong>today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement.</p> <p align="justify">The transaction provides OPKO with additional non-dilutive capital while preserving significant long-term http://www.streetinsider.com/Globe+Newswire/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html Thu, 13 Aug 2026 09:15:00 -0400 A.50202447 KKR O.02783319 O.14891823 O.51351764 OPK http://www.streetinsider.com/Globe+Newswire/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html <p align="justify">MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- <strong>OPKO Health, Inc. (NASDAQ: OPK) </strong>today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement.</p> <p align="justify">The transaction provides OPKO with additional non-dilutive capital while preserving significant long-term http://www.streetinsider.com/Globe+Newswire/OPKO+Health+Expands+Strategic+Relationship+with+HealthCare+Royalty+Through+%24125+Million+Notes+Issuance+Secured+by+Mazdutide+Royalty+Interests/26917615.html Thu, 13 Aug 2026 09:15:00 -0400 A.50202447 KKR O.02783319 O.14891823 O.51351764 OPK http://www.streetinsider.com/Equity+Offerings/Opko+Health+invests+%245M+in+Cocrystal+Pharma+via+private+placement/26853695.html <p>Cocrystal Pharma (NASDAQ: COCP) announced a $5 million private placement with OPKO Health (NASDAQ: OPK), under which OPKO purchased 5,474,053 shares of Cocrystal common stock at $0.9134 per share, based on the Nasdaq Consolidated Bid Price on the trading day of closing. No warrants or other derivative securities were included in the transaction.</p> <p>The shares were sold as unregistered securities under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. OPKO is described in the press release as a longtime investor in Cocrystal.</p> <p>James Sapirstein, Chief Executive Officer of Cocrystal Pharma, said the company expects to report topline data from http://www.streetinsider.com/Equity+Offerings/Opko+Health+invests+%245M+in+Cocrystal+Pharma+via+private+placement/26853695.html Mon, 03 Aug 2026 07:00:12 -0400 COCP OPK http://www.streetinsider.com/Equity+Offerings/Opko+Health+invests+%245M+in+Cocrystal+Pharma+via+private+placement/26853695.html <p>Cocrystal Pharma (NASDAQ: COCP) announced a $5 million private placement with OPKO Health (NASDAQ: OPK), under which OPKO purchased 5,474,053 shares of Cocrystal common stock at $0.9134 per share, based on the Nasdaq Consolidated Bid Price on the trading day of closing. No warrants or other derivative securities were included in the transaction.</p> <p>The shares were sold as unregistered securities under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. OPKO is described in the press release as a longtime investor in Cocrystal.</p> <p>James Sapirstein, Chief Executive Officer of Cocrystal Pharma, said the company expects to report topline data from http://www.streetinsider.com/Equity+Offerings/Opko+Health+invests+%245M+in+Cocrystal+Pharma+via+private+placement/26853695.html Mon, 03 Aug 2026 07:00:12 -0400 COCP OPK http://www.streetinsider.com/Press+Releases/Cocrystal+Pharma+Announces+%245+Million+Private+Placement+with+OPKO+Health/26853661.html <p align="center"><i>Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026</i></p> <p align="justify">BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel antiviral therapeutics, today announced a $5 million investment from OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), a longtime investor in the Company, has increased its position through a $5 million investment as the Company advances its lead norovirus program toward Phase 1b topline data later this year.</p> <p align="justify">Under the terms of the agreement, Cocrystal http://www.streetinsider.com/Press+Releases/Cocrystal+Pharma+Announces+%245+Million+Private+Placement+with+OPKO+Health/26853661.html Mon, 03 Aug 2026 07:00:00 -0400 COCP OPK